Flagship Biosciences to Demonstrate Benefits of Computational Tissue Analysis for Clinical Pipeline Decisions at ASCO

The benefits of increased confidence and clarity for clinical trial decisions will be presented by Flagship’s team at the Annual Meeting of the American Society of Clinical Oncology, June 2nd – 6th, at McCormick Place, Chicago, IL. Visit Flagship at @ASCO booth #25115 and learn more about Flagship’s plans for the meeting at BioSpace.

Read More

Is PD-L1 Harmonization on the Horizon?

Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not only calibrate results across multiple assays, but can optimize cutoff points for patient […]

Read More

Flagship Biosciences to present quantitative tissue-based data on five clinical trial and immuno-oncology topics at AACR

Flagship Biosciences’ Computational Tissue Analysis (cTA™) and decision support platform featured in five scientific poster presentations at the American Association for Cancer Research Annual Meeting, April 1-5, 2017, in Washington, D.C. Visit Flagship at @AACR booth #1553 and learn more about the posters at BioSpace.

Read More

Flagship Biosciences to exhibit at SITC Annual Meeting 2016 with two immune cell analysis posters

Booth #127 November 11-13, National Harbor, MD National Harbor, MD – Nov. 2 2016 – Flagship Biosciences, the leader in tissue image analysis, announced today that they will be presenting new data at the Annual Meeting of the Society for Immunotherapy of Cancer being held November 11-13, with exhibits from Nov. 11-12. Flagship’s scientists will […]

Read More

Flagship’s computational Tissue Analysis (cTA™) tools support Summit’s DMD drug development

Flagship develops cTA™ tools and duplex IHC assays for muscle biopsy evaluation in support of disease-modifying therapies for Duchenne muscular dystrophy Granada, Spain – October 18th, 2016 – Data and findings featuring Flagship’s computational Tissue Analysis (cTA™) in the development of biomarker analysis tools to support Duchenne muscular dystrophy (DMD) drug development were presented by […]

Read More

Flagship Biosciences to exhibit at ASCO Annual Meeting 2016

Booth #19122 June 3-7, McCormick Place, Chicago, IL May 25, 2016 – Westminster, CO – Flagship Biosciences, the leader in tissue image analysis, announced today that they will be exhibiting at the American Society for Clinical Oncology (ASCO) at McCormick Place in Chicago, IL for the ASCO Annual Meeting being held June 3rd to June […]

Read More

Dr. Nancy Gillett Joins Flagship's Board of Directors

Former Charles River Laboratories CSO broadens Flagship’s leadership expertise Westminster, CO – May 3, 2016 – Flagship Biosciences, the leader in tissue image analysis, announced the addition of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, in her last position, she served as Corporate Executive […]

Read More

Flagship to exhibit at AACR Annual Meeting 2016 with three immuno-oncology presentations

Booth #2634, April 16-20, Ernest N. Memorial Convention Center, New Orleans, LA Westminster, CO – April 13, 2016 – Flagship is pleased to announce that they will be exhibiting at the AACR Annual Meeting in New Orleans from April 16th-20th. AACR’s Annual meeting is one of the largest oncology conferences bringing together cancer researchers and […]

Read More

Flagship Biosciences expands operations to meet tremendous industry growth demands

Escalated demand for Flagship’s tissue analysis capabilities are being driven by proven success. Westminster, CO – March 15, 2016 – Flagship’s track record of success has increased the adoption of the company’s technology and the demand for their specialty tissue image analysis solutions. To meet this demand, the company has expanded its facilities and staff, […]

Read More

Flagship Biosciences and Beaufort, LLC partner to provide Clinical Trial Services for the Pharmaceutical Industry

Flagship Biosciences establishes partnership with Beaufort, an industry-leading CRO, to provide a full range of clinical trial services to advance initiatives that bring image analysis based Companion Diagnostics (CDx) into the clinical market. Westminster, CO – February 2, 2016 – Flagship Biosciences, Inc. announces that Beaufort, LLC., www.beaufortcro.com, an industry leading diagnostic-CRO with extensive experience […]

Read More